Lung transplant outcomes in myositis, systemic sclerosis and idiopathic pulmonary fibrosis: a multicenter retrospective analysis

OBJECTIVES: To describe clinical characteristics and post-lung transplant outcomes of patients with idiopathic inflammatory myopathies (IIM),systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). METHODS: We retrospectively analyzed interstitial lung disease (ILD) patients with IIM (n = 22), SSc (n = 32), and IPF (n = 64) who underwent lung transplantation (2012-2024) at two Canadian centers, Vancouver and Montréal. RESULTS: Among IIM patients, 41% was clinically amyopathic at presentation, and 45% had anti-MDA5 dermatomyositis (DM), all with rapid progressive (RP)-ILD, 32% anti-synthetase syndrome, 14% overlap myositis, and 9% other DM. In SSc, 88% had pulmonary hypertension (PH) (31% severe) and 78% had esophageal dysmotility. IIM patients required more frequent pre-transplant ICU admission and emergency transplantation. Post-transplant, IIM patients had longer ICU/hospital stays. There were no significant differences in 1-year survival, survival at last follow-up (median: 2.8 years for IIM, 2.5 years for SSc, and 3.6 years for IPF), incidence of chronic lung allograft dysfunction, or malignancy. Subgroup analyses of IIM (stratified by transplant urgency, extracorporeal membrane oxygenation (ECMO) support, and amyopathy) and SSc (stratified by severe PH, esophageal dysmotility, and transplant urgency) showed no significant differences in long-term survival. No autoimmune disease recurrence was observed. CONCLUSION: Despite their underlying autoimmune diseases, post-transplant survival outcomes of selected IIM and SSc patients did not differ significantly from those with IPF. IIM patients with RP-ILD necessitating emergency transplantation and ECMO support exhibited survival similar to those without such complications. However, their more complex pre- and post-transplant courses emphasize the necessity for individualized lung transplant strategies and a multidisciplinary management approach.

Authors

Institutions

Publication Details

Journal
Lara D. Veeken
Published
2026-04-14
DOI
https://doi.org/10.1093/rheumatology/keag200
Primary Topic
Transplantation: Methods and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lung transplant outcomes in myositis, systemic sclerosis and idiopathic pulmonary fibrosis: a multicenter retrospective analysis

Navid B. Saleh, Kun Huang, Sabrina Hoa, Alec Yu et al.
Lara D. Veeken
Transplantation: Methods and Outcomes
article

Lung transplant outcomes in myositis, systemic sclerosis and idiopathic pulmonary fibrosis: a multicenter retrospective analysis

Navid B. Saleh, Kun Huang, Sabrina Hoa, Alec Yu, R.D. Levy, Hyein Kim, John Yee, James Choi, Jennifer M Wilson, Océane Landon Cardinal, Angela Chang, Darya S Jalaledin, Charles D Poirier
article en

Abstract

OBJECTIVES: To describe clinical characteristics and post-lung transplant outcomes of patients with idiopathic inflammatory myopathies (IIM),systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). METHODS: We retrospectively analyzed interstitial lung disease (ILD) patients with IIM (n = 22), SSc (n = 32), and IPF (n = 64) who underwent lung transplantation (2012-2024) at two Canadian centers, Vancouver and Montréal. RESULTS: Among IIM patients, 41% was clinically amyopathic at presentation, and 45% had anti-MDA5 dermatomyositis (DM), all with rapid progressive (RP)-ILD, 32% anti-synthetase syndrome, 14% overlap myositis, and 9% other DM. In SSc, 88% had pulmonary hypertension (PH) (31% severe) and 78% had esophageal dysmotility. IIM patients required more frequent pre-transplant ICU admission and emergency transplantation. Post-transplant, IIM patients had longer ICU/hospital stays. There were no significant differences in 1-year survival, survival at last follow-up (median: 2.8 years for IIM, 2.5 years for SSc, and 3.6 years for IPF), incidence of chronic lung allograft dysfunction, or malignancy. Subgroup analyses of IIM (stratified by transplant urgency, extracorporeal membrane oxygenation (ECMO) support, and amyopathy) and SSc (stratified by severe PH, esophageal dysmotility, and transplant urgency) showed no significant differences in long-term survival. No autoimmune disease recurrence was observed. CONCLUSION: Despite their underlying autoimmune diseases, post-transplant survival outcomes of selected IIM and SSc patients did not differ significantly from those with IPF. IIM patients with RP-ILD necessitating emergency transplantation and ECMO support exhibited survival similar to those without such complications. However, their more complex pre- and post-transplant courses emphasize the necessity for individualized lung transplant strategies and a multidisciplinary management approach.

Lara D. Veeken
University of British Columbia (CA), Surrey Memorial Hospital (CA), Vancouver General Hospital (CA), Research Canada (CA), Centre Hospitalier de l’Université de Montréal (CA)
Good health and well-being
Openalex Percentile: Top 25%
Transplantation: Methods and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.